Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma. METHODS: In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors. RESULTS: Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group. The median duration of response was not reached in either group. The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001). Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors. Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy. Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication. CONCLUSIONS: The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy. Combination therapy had an acceptable safety profile. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01927419.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“(% [95% CI])† 44 (61 [49–72]) 4 (11 [3–25]) 12 (52 [31–73]) 1 (10 [0–45])”
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Not reported 1 (1) 1 (3) 1 (1) 1 (2) 2 (1)”
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“>ULN 15 (21) 7 (19) 24 (25) 11 (23) 35 (25)”
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 3×
“Stable disease 9 (12) 13 (35) 3 (13) 1 (10)”
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“M1b 22 (31) 8 (22) 27 (28) 12 (26) 39 (27)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 4×
“Increased lipase 12 (13) 8 (9) 2 (4) 1 (2)”
InfluentialSelf-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citation
Cited by
Items 401–500 of 1,008
Barrett, M. T., Anderson, K. S., Lenkiewicz, E., Andreozzi, M., Cunliffe, H. E., Klassen, C. L., Dueck, A. C., McCullough, A. E., Reddy, S. K., Ramanathan, R. K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4494 · Cited by 134
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016
Clark, P. E., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Efstathiou, J. A., Flaig, T. W., Friedlander, T. W., Greenberg, R. E., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0131 · Cited by 135
Role of immune cells in pancreatic cancer from bench to clinical application: An updated review
Chang, J. H., Jiang, Y., & Pillarisetty, V. G. (2016) · Medicine · doi:10.1097/md.0000000000005541 · Cited by 151
Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies
Mattia, G., Puglisi, R., Ascione, B., Malorni, W., Carè, A., & Matarrese, P. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0059-7 · Cited by 152
Immune checkpoint blockade therapy
Wieder, T., Eigentler, T., Brenner, E., & Röcken, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.042 · Cited by 152
Larimer, B. M., Bloch, E., Nesti, S., Austin, E. E., Wehrenberg-Klee, E. P., Boland, G. M., & Mahmood, U. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2407 · Cited by 133
Kooshkaki, O., Derakhshani, A., Hosseinkhani, N., Torabi, M., Safaei, S., Brunetti, O., Racanelli, V., Silvestris, N., & Baradaran, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124427 · Cited by 147
“[65] 2 Arm 1: Nivolumab (1 mg/kg+ Ipilimumab (3 mg/kg) Arm 2: Placebo + Ipilimumab Percentage of participants with OR in the randomized, BRAF wild-type population (at a minimum of 6 months) Among patients with BRAF wild-type tumors, the rate of OR was 61% in the combination group versus 11% in the ipilimumab-monothera…”
BackgroundHarnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene
Fontanals-Cirera, B., Hasson, D., Vardabasso, C., Di Micco, R., Agrawal, P., Chowdhury, A., Gantz, M., de Pablos-Aragoneses, A., Morgenstern, A., Wu, P., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.11.004 · Cited by 132
The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology
American Society of Clinical Oncology (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.010462 · Cited by 132
Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer
Geukes Foppen, M. H., Donia, M., Svane, I. M., & Haanen, J. B. A. G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.018 · Cited by 131
Xu, W., Hiếu, T., Malarkannan, S., & Wang, L. L. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.148 · Cited by 145
Mechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 130
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 147
Harrington, K. J., Puzanov, I. J., Hecht, J. R., Hodi, F. S., Szabó, Z. R., Murugappan, S., & Kaufman, H. L. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1115725 · Cited by 144
Self-citationImmunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Bertucci, F., & Gonçalvès, A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0627-0 · Cited by 138
Davies, M., & Duffield, E. A. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s141577 · Cited by 128
Hong, X., Sullivan, R. J., Kalinich, M., Kwan, T. T., Giobbie‐Hurder, A., Pan, S., LiCausi, J. A., Milner, J. D., Nieman, L. T., Wittner, B. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719264115 · Cited by 132
Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer
Fox, E. E., Oliver, T., Rowe, M. M., Thomas, S., Zakharia, Y., Gilman, P. B., Muller, A. J., & Prendergast, G. C. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00370 · Cited by 136
Capozzi, M., Divitiis, C. D., Ottaiano, A., von Arx, C., Scala, S., Tatangelo, F., Delrio, P., & Tafuto, S. (2019) · Cancer Management and Research · doi:10.2147/cmar.s188316 · Cited by 138
Tumor-on-chip modeling of organ-specific cancer and metastasis
Del Piccolo, N., Shirure, V. S., Bi, Y., Goedegebuure, S. P., Gholami, S., Hughes, C. C. W., Fields, R. C., & George, S. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.008 · Cited by 126
Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy
Larimer, B. M., Wehrenberg-Klee, E. P., Caraballo, A., & Mahmood, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.173930 · Cited by 131
Peptide-based materials for cancer immunotherapy
Zhang, L., Huang, Y., Lindstrom, A. R., Lin, T., Lam, K. S., & Li, Y. (2019) · Theranostics · doi:10.7150/thno.37194 · Cited by 138
“Checkpoint blockade immunotherapy is one of the newest therapeutic approaches to help restore the immune system’s ability to find and attack hidden cancer cells [81-87].”
BackgroundRisk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Abdel-Rahman, O. M., & Fouad, M. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816636557 · Cited by 126
Tsai, H.-F., & Hsu, P. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0341-0 · Cited by 146
Redelman‐Sidi, G., Michielin, O. A., Cervera, C., Ribi, C., Aguado, J. M., Fernández‐Ruiz, M., & Manuel, O. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.030 · Cited by 135
Zappasodi, R., Budhu, S., Hellmann, M. D., Postow, M. A., Şenbabaoğlu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., Li, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.007 · Cited by 129
Self-citationWagner, N. B., Forschner, A., Leiter, U., Garbe, C., & Eigentler, T. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0167-x · Cited by 137
The Evolving Modern Management of Brain Metastasis
Fecci, P. E., Champion, C. D., Hoj, J. P., McKernan, C., Goodwin, C. R., Kirkpatrick, J. P., Anders, C. K., Pendergast, A. M., & Sampson, J. H. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1624 · Cited by 138
“While several targeted agents are approved inNSCLCharboring an EGFRmutation, resistance emerges through the T790Mmutation (89).”
BackgroundInfluentialIncreased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
Mei, Y., Bi, W. L., Greenwald, N. F., Du, Z., Agar, N. Y. R., Kaiser, U. B., Woodmansee, W. W., Reardon, D. A., Freeman, G. J., Fecci, P. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12088 · Cited by 132
Rosner, S., Kwong, E., Shoushtari, A. N., Friedman, C. F., Warner, A. B., Brady, M. S., Coit, D. G., Callahan, M. K., Wolchok, J. D., Chapman, P. B., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1356 · Cited by 132
Self-citationRole of immune-checkpoint inhibitors in lung cancer
Jain, P., Jain, C., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817750075 · Cited by 144
Girotra, M., Hansen, A. R., Farooki, A., Byun, D. J., Min, L., Creelan, B., Callahan, M. K., Atkins, M. B., Sharon, E., Antonia, S. J., et al. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky021 · Cited by 132
Zhang, Y., Du, X., Liu, M., Tang, F., Zhang, P., Ai, C., Fields, J. K., Sundberg, E. J., Latinovic, O., Devenport, M., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0184-1 · Cited by 127
Cardiotoxicity from immune checkpoint inhibitors
Michel, L., Rassaf, T., & Totzeck, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100420 · Cited by 150
Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy
Morse, M. A., Höchster, H. S., & Benson, A. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0176 · Cited by 140
“In two melanoma trials, nivolumab plus ipilimumab significantly improved PFS versus ipilimumab alone [29, 30].”
BackgroundRecent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0541-9 · Cited by 121
Combatting Mucosal Melanoma: Recent Advances and Future Perspectives
Tyrrell, H. E. J., & Payne, M. (2018) · Melanoma Management · doi:10.2217/mmt-2018-0003 · Cited by 138
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
Immunotherapy of Neuroblastoma: Facts and Hopes
Anderson, J., Majzner, R. G., & Sondel, P. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1356 · Cited by 142
“The cancer immunotherapy revolution is exemplified by the outstanding success of checkpoint inhibitors in melanoma (1) and certain adult carcinomas (2) and chimeric antigen receptor T (CAR-T) cells in both adult and pediatric hematologic malignancies (3, 4).”
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Colen, R. R., Fujii, T., Bilen, M. A., Kotrotsou, A., Abrol, S., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0524-2 · Cited by 120
Rini, B. I., McDermott, D. F., Hammers, H. J., Bro, W., Bukowski, R. M., Faba, B., Faba, J., Figlin, R. A., Hutson, T. E., Jonasch, E. W., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0180-7 · Cited by 125
Self-citationQueirolo, P., & Spagnolo, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.002 · Cited by 129
Cancer biomarkers for targeted therapy
Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0178-7 · Cited by 120
Shien, K., Papadimitrakopoulou, V. A., & Wistuba, I. I. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.016 · Cited by 124
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mössner, R., Ugurel, S., Zimmer, L., Gutzmer, R., & for the “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO) (2016) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047 · Cited by 118
Williams, N. L., Wuthrick, E. J., Kim, H. J., Palmer, J. D., Garg, S., Eldredge-Hindy, H., Daskalakis, C., Feeney, K. J., Mastrangelo, M. J., Kim, L. J., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.028 · Cited by 123
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
Audrito, V., Serra, S., Stingi, A., Orso, F., Gaudino, F., Bologna, C., Neri, F., Garaffo, G., Nassini, R., Baroni, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15213 · Cited by 118
Immune checkpoint blockade opens a new way to cancer immunotherapy
Sadreddini, S., Baradaran, B., Aghebati‐Maleki, A., Sadreddini, S., Shanehbandi, D., Fotouhi, A., & Maleki, L. A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27816 · Cited by 132
George, J., Bajaj, D., Sankaramangalam, K. P., Yoo, J. W., Joshi, N. S., Gettinger, S. N., Price, C. C., & Farrell, J. J. (2019) · Pancreatology · doi:10.1016/j.pan.2019.04.015 · Cited by 123
Arriola, E., Wheater, M. J., Galea, I., Cross, N., Maishman, T., Hamid, D., Stanton, L., Cave, J., Geldart, T., Mulatero, C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.028 · Cited by 128
Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.007 · Cited by 123
Hyponatraemia secondary to nivolumab-induced primary adrenal failure
Trainer, H., Hulse, P., Higham, C. E., Trainer, P., & Lorigan, P. (2016) · Endocrinology, Diabetes & Metabolism Case Reports · doi:10.1530/edm-16-0108 · Cited by 117
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 124
Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Rosenblatt, J., & Avigan, D. (2017) · Blood · doi:10.1182/blood-2016-08-731885 · Cited by 117
Chesney, J. A., Mitchell, R. A., & Yaddanapudi, K. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-458rrr · Cited by 124
Self-citationCancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
Gatti-Mays, M. E., Redman, J. M., Collins, J. M., & Bilusic, M. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1364322 · Cited by 116
Brown, Z. J., Yu, S. J., Heinrich, B., Ma, C., Fu, Q., Sandhu, M., Agdashian, D., Zhang, Q., Korangy, F., & Greten, T. F. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2190-4 · Cited by 122
Kvarnhammar, A. M., Veitonmäki, N., Hägerbrand, K., Dahlman, A., Smith, K. E., Fritzell, S., von Schantz, L., Thagesson, M., Werchau, D., Smedenfors, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0570-8 · Cited by 115
Pucelik, B., Arnaut, L. G., Stochel, G., & Dąbrowski, J. M. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b07031 · Cited by 124
Roszik, J., Haydu, L. E., Hess, K. R., Oba, J., Joon, A. Y., Siroy, A. E., Karpinets, T. V., Stingo, F. C., Baladandayuthapani, V., Tetzlaff, M. T., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0705-4 · Cited by 115
Burova, E., Hermann, A., Waite, J., Potocky, T., Lai, V., Hong, S., Liu, M., Allbritton, O., Woodruff, A., Wu, Q., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0665 · Cited by 114
Combinatorial therapy in tumor microenvironment: Where do we stand?
Kumari, S., Advani, D., Sharma, S., Ambasta, R. K., & Kumar, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188585 · Cited by 130
Immune checkpoint inhibitor-related hepatotoxicity: A review
Remash, D., Prince, D. S., McKenzie, C. A., Strasser, S. I., Kao, S., & Liu, K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5376 · Cited by 133
Wu, J., Fu, J., Zhang, M., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0188-3 · Cited by 124
Zhou, X.-M., Li, W.-Q., Wu, Y.-H., Han, L., Cao, X.-G., Yang, X.-M., Wang, H.-F., Zhao, W.-S., Zhai, W.-J., Qi, Y.-M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02821 · Cited by 113
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue
Li, Z., Tuong, Z. K., Dean, I., Willis, C., Gaspal, F., Fiancette, R., Idris, S., Kennedy, B. C., Ferdinand, J. R., Peñalver, A., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20210749 · Cited by 126
Chae, Y. K., Pan, A. P., Davis, A. A., Raparia, K., Mohindra, N. A., Matsangou, M., & Giles, F. J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.011 · Cited by 126
Merkel Cell Carcinoma Therapeutic Update
Cassler, N. M., Merrill, E. D., Bichakjian, C. K., & Brownell, I. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0409-1 · Cited by 127
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 123
New emerging targets in cancer immunotherapy: the role of LAG3
Puhr, H. C., & Ilhan‐Mutlu, A. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000482 · Cited by 130
Lopci, E., Hicks, R. J., Dimitrakopoulou‐Strauss, A., Dercle, L., Iravani, A., Seban, R., Sachpekidis, C., Humbert, O., Gheysens, O. S., Glaudemans, A. W. J. M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05780-2 · Cited by 128
Combination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
“Physicians might adjust the concentrations of drugs within a combination therapeutic to enhance targeted inhibition and to optimize synergy between drugs [28].”
BackgroundUgurel, S., Röhmel, J., Ascierto, P. A., Becker, J. C., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Livingstone, E., Long, G. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.021 · Cited by 122
Self-citationIL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0682 · Cited by 111
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Botticelli, A., Onesti, C. E., Zizzari, I. G., Cerbelli, B., Sciattella, P., Occhipinti, M. A., Roberto, M., Pietro, F. R. D., Bonifacino, A., Ghidini, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22242 · Cited by 120
Armand, P. A., Lesokhin, A. M., Borrello, I., Timmerman, J. M., Gutierrez, M. E., Zhu, L., McKiver, M. P., & Ansell, S. M. (2020) · Leukemia · doi:10.1038/s41375-020-0939-1 · Cited by 120
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
Varghese, A. M., Arora, A., Capanu, M., Camacho, N., Won, H. H., Zehir, A., Gao, J., Chakravarty, D., Schultz, N. D., Klimstra, D. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx545 · Cited by 117
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Cadranel, J. L., Canellas, A., Matton, L., Darrason, M., Parrot, A., Naccache, J., Lavolé, A., Ruppert, A.-M., & Fallet, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0058-2019 · Cited by 117
Evolving impact of long-term survival results on metastatic melanoma treatment
Michielin, O. A., Atkins, M. B., Koon, H. B., Dummer, R., & Ascierto, P. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000948 · Cited by 125
Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
Diesendruck, Y., & Benhar, I. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.001 · Cited by 114
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
Bartee, M. Y., Dunlap, K. M., & Bartee, E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1638 · Cited by 115
Nomizo, T., Ozasa, H., Tsuji, T., Funazo, T. Y., Yasuda, Y., Yoshida, H., Yagi, Y., Sakamori, Y., Nagai, H., Hirai, T., et al. (2017) · Scientific Reports · doi:10.1038/srep45124 · Cited by 117
Combinatorial Cancer Immunotherapies
Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.005 · Cited by 118
Self-citationThe use of immunotherapy in the treatment of melanoma
Achkar, T., & Tarhini, A. A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0458-3 · Cited by 118
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
Kang, J. H., Bluestone, J. A., & Young, A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.006 · Cited by 118
Targeting C-Type Lectin Receptors for Cancer Immunity
Yan, H., Kamiya, T., Suabjakyong, P., & Tsuji, N. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00408 · Cited by 124
Ligero, M., Garcia-Ruiz, A., Viaplana, C., Villacampa, G., Raciti, M. V., Landa, J., Matos, I., Martin-Liberal, J., Ochoa-de-Olza, M., Hierro, C., et al. (2021) · Radiology · doi:10.1148/radiol.2021200928 · Cited by 107
Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity
Michel, L., Rassaf, T., & Totzeck, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.15 · Cited by 122
Checkpoint Inhibitor–Induced Colitis
Bellaguarda, E., & Hanauer, S. B. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000497 · Cited by 118
Yang, Y. P., Xu, J., Sun, Y., Mo, L., Liu, B., Pan, X., Liu, Z., & Tan, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c02016 · Cited by 108
Engineered materials for cancer immunotherapy
Cheung, A. S., & Mooney, D. J. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.007 · Cited by 111
Chae, Y. K., Chung, S. Y., Davis, A. A., Carneiro, B. A., Chandra, S., Kaplan, J. B., Kalyan, A., & Giles, F. J. (2015) · Oncotarget · doi:10.18632/oncotarget.5076 · Cited by 116
Zhu, Z., Liu, W., & Gotlieb, V. K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.002 · Cited by 120
Immuno-oncology combinations: raising the tail of the survival curve
Harris, S. J., Harris, S. J., Brown, J. S., Lopez, J. S., Yap, T. A., Brown, J. S., Lopez, J. S., & Yap, T. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0015 · Cited by 114
Singh, M., Vianden, C., Cantwell, M. J., Dai, Z., Xiao, Z., Sharma, M., Khong, H., Jaiswal, A. R., Fa’ak, F., Hailemichael, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01572-7 · Cited by 112
Mullinax, J. E., Hall, M. S., Prabhakaran, S., Weber, J. S., Khushalani, N. I., Eroglu, Z., Brohl, A. S., Markowitz, J., Royster, E. B., Richards, A. D., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00044 · Cited by 113
Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management
Grover, S., Rahma, O. E., Hashemi, N., & Lim, R. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100013 · Cited by 116
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
Onoyama, T., Takeda, Y., Yamashita, T., Hamamoto, W., Sakamoto, Y., Koda, H., Kawata, S., Matsumoto, K., & Isomoto, H. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i3.353 · Cited by 104
Assessing the future of solid tumor immunotherapy
Guha, P., Heatherton, K. R., O’Connell, K. P., Alexander, I. S., & Katz, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030655 · Cited by 105
“In a phase 1 study, an ipilimumab and nivolumab combination was reported to increase the objective response rate to 61% (n = 44/72), with complete responses seen in 22% (n = 16/72) of patients [59].”
BackgroundChallenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
Postel-Vinay, S. C., Aspeslagh, S., Lanoy, É., Robert, C., Soria, J., & Marabelle, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv550 · Cited by 117
Self-citation
Metadata
- Authors
- Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D., Salama, A. K., Taylor, M., Ott, P. A., Rollin, L. M., Horak, C., Gagnier, P., Wolchok, J. D., & Hodi, F. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Université Paris-Sud (FR)
- Beth Israel Deaconess Medical Center (US)
- From Memorial Sloan Kettering Cancer Center (M.A.P., J.D.W.), Weill Cornell Medical College (M.A.P., J.D.W.), and New York University, Perlmutter Cancer Center (A.C.P.) — all in New York; J. Graham Brown Cancer Center, University of Louisville, Louisville, KY (J.C.); Institute Gustave Roussy, Villejuif (C.R.), Paris-Sud University, Orsay (C.R.), and Institut Universitaire du Cancer, Toulouse (N.M.) — all in France; Huntsman Cancer Institute, Salt Lake City (K.G.); Beth Israel Deaconess Medical Center (D....
- Prisma Health (US)
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-21
- Volume
- 372
- Issue
- 21
- Pages
- 2006-2017
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5744258
- OpenAlex
- W2128758225
- Cited by
- 2,781
- References
- 28
- Citations by year
- 2026: 53 · 2025: 91 · 2024: 131 · 2023: 175 · 2022: 174 · 2021: 206 · 2020: 261 · 2019: 277 · 2018: 372 · 2017: 449 · 2016: 402 · 2015: 183
- FWCI
- 204.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, metastatic melanoma, combination immunotherapy, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, objective response rate, progression-free survival, BRAF V600 mutation, immune-related adverse events, first-line therapy, dose escalation, complete response, duration of response
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Disease-Free Survival, Tumor Burden, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.